Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification
The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Abstract
Clinical studies with the Abl tyrosine kinase inhibitor STI-571 in chronic myeloid leukemia demonstrate that many patients with advanced stage disease respond initially but then relapse. Through biochemical and molecular analysis of clinical material, we find that drug resistance is associated with the reactivation of BCR-ABL signal transduction in all cases examined. In six of nine patients, resistance was associated with a single amino acid substitution in a threonine residue of the Abl kinase domain known to form a critical hydrogen bond with the drug. This substitution of threonine with isoleucine was sufficient to confer STI-571 resistance in a reconstitution experiment. In three patients, resistance was associated with progressive BCR-ABL gene amplification. These studies provide evidence that genetically complex cancers retain dependence on an initial oncogenic event and suggest a strategy for identifying inhibitors of STI-571 resistance.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In contrast to some targeted therapies for which dominant mechanisms of resistance have been observed, such as BCR-ABL mutations that cause resistance to imatinib in chronic myeloid leukemia,22 KRASG12C-mutant cancers appear to evolve diverse mechanisms of resistance to adagrasib.”
From Acquired Resistance to KRAS G12C Inhibition in Cancer (2021) · cites this paper as [22]
Citations
Cites
Thompson, J. (1997) · Nucleic Acids Research · doi:10.1093/nar/25.24.4876 · Cited by 38,993
Druker, B. J., Talpaz, M., Resta, D. J., Peng, B., Buchdunger, E., Ford, J. M., Lydon, N. B., Kantarjian, H., Capdeville, R., Ohno-Jones, S., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200104053441401 · Cited by 5,243
Self-citationEffects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells
Druker, B. J., Tamura, S., Buchdunger, E., Ohno, S., Segal, G. M., Fanning, S., Zimmermann, J., & Lydon, N. B. (1996) · Nature Medicine · doi:10.1038/nm0596-561 · Cited by 2,967
Druker, B. J., Sawyers, C. L., Kantarjian, H., Resta, D. J., Reese, S. F., Ford, J. M., Capdeville, R., & Talpaz, M. (2001) · New England Journal of Medicine · doi:10.1056/nejm200104053441402 · Cited by 2,713
Self-citationStructural Mechanism for STI-571 Inhibition of Abelson Tyrosine Kinase
Schindler, T., Bornmann, W., Pellicena, P., Miller, W. T., Clarkson, B., & Kuriyan, J. (2000) · Science · doi:10.1126/science.289.5486.1938 · Cited by 1,780
Daley, G. Q., Van Etten, R. A., & Baltimore, D. (1990) · Science · doi:10.1126/science.2406902 · Cited by 1,756
Sawyers, C. L. (1999) · New England Journal of Medicine · doi:10.1056/nejm199904293401706 · Cited by 1,621
Self-citationThe Biology of Chronic Myeloid Leukemia
Faderl, S., Talpaz, M., Estrov, Z., O'Brien, S., Kurzrock, R., & Kantarjian, H. M. (1999) · New England Journal of Medicine · doi:10.1056/nejm199907153410306 · Cited by 1,302
Reversible Tumorigenesis by MYC in Hematopoietic Lineages
Felsher, D. W., & Bishop, J. M. (1999) · Molecular Cell · doi:10.1016/s1097-2765(00)80367-6 · Cited by 881
Essential role for oncogenic Ras in tumour maintenance
Chin, L., Tam, A., Pomerantz, J., Wong, M., Holash, J., Bardeesy, N., Shen, Q., O'Hagan, R., Pantginis, J., Zhou, H., et al. (1999) · Nature · doi:10.1038/22788 · Cited by 875
Cited by
Items 901–1,000 of 1,008
The Biology and Targeting of FLT3 in Pediatric Leukemia
Annesley, C., & Brown, P. A. (2014) · Frontiers in Oncology · doi:10.3389/fonc.2014.00263 · Cited by 67
“In BCR-ABL leukemia, the selection of clones that harbor mutations in the ATP-binding pocket and prevent the binding of imatinib is the most common cause of drug resistance (160).”
BackgroundMedicinal Chemistry Strategies for the Development of Kinase Inhibitors Targeting Point Mutations
Lu, X., Smaill, J. B., & Ding, K. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c00507 · Cited by 67
Waller, C. F. (2009) · Recent results in cancer research/Recent Results in Cancer Research · doi:10.1007/978-3-642-01222-8_1 · Cited by 75
Borkhardt, A. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00129-0 · Cited by 67
Resistance in the land of molecular cancer therapeutics
Shannon, K. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00101-0 · Cited by 67
“One such mechanism—genomic amplification of BCR-ABL—has been described in imatinib-treated patients (Gorre et al., 2001).”
BackgroundChen, J., Wall, N. R., Kocher, K., Duclos, N., Fabbro, D., Neuberg, D. S., Griffin, J. D., Shi, Y., & Gilliland, D. G. (2004) · Journal of Clinical Investigation · doi:10.1172/jci20673 · Cited by 70
“corresponds to the T315I mutation in ABL, a common resistance mutation in BCR-ABL+ CML patients who relapse while on imatinib therapy (6, 7).”
BackgroundDing, K., Su, Y., Pang, L., Lu, Q., Wang, Z., Zhang, S., Zheng, S. S., Mao, J., & Zhu, Y. (2008) · Carcinogenesis · doi:10.1093/carcin/bgn251 · Cited by 66
Linking somatic genetic alterations in cancer to therapeutics
Stuart, D. D., & Sellers, W. R. (2009) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2009.02.001 · Cited by 68
Arunasree, K. M., Roy, K. R., Anilkumar, K., Aparna, A., Reddy, G. V., & Reddanna, P. (2008) · Leukemia Research · doi:10.1016/j.leukres.2007.11.007 · Cited by 67
Personalized medicine in non-small cell lung cancer: a review from a pharmacogenomics perspective
Jiang, W., Cai, G., Hu, P. C., & Wang, Y. (2018) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2018.04.005 · Cited by 72
Mechanisms of resistance to FLT3 inhibitors
Chu, S. H., & Small, D. (2009) · Drug Resistance Updates · doi:10.1016/j.drup.2008.12.001 · Cited by 69
“A uthor M anuscript A uthor M anuscript A uthor M anuscript A uthor M anuscript binding of imatinib to the ATP binding pocket of BCR–ABL have been the most frequently observed cause of acquired resistance to imatinib in CML patients (Gorre et al., 2001; Wadleigh et al., 2005).”
Advanced-phase chronic myeloid leukemia
Cortes, J. E., & Kantarjian, H. M. (2003) · Seminars in Hematology · doi:10.1016/s0037-1963(03)70045-6 · Cited by 73
Maekawa, T., Ashihara, E., & Kimura, S. H. (2007) · International Journal of Clinical Oncology · doi:10.1007/s10147-007-0699-1 · Cited by 72
“Resistance to IM may occur through several mechanisms; overexpression of Bcr-Abl and amplifi cation of the Bcr-Abl gene,(42) involvement of P-glycoprotein, activation of Lyn, an increase of α-acid glycoprotein in the serum,(49) a low expression of human organic cation transporter 1 (hOCT1),(50) and most intriguingly,…”
BackgroundCancer: the evolved consequence of a destabilized genome
Anderson, G. R., Stoler, D. L., & Brenner, B. M. (2001) · BioEssays · doi:10.1002/bies.1149 · Cited by 73
“Excellent responses may be achieved with general anti-proliferative agents; molecularly targeted agents also show considerable promise, such as STI-571 for CML, although even here drug-resistant cells become selected for.((51)) For solid tumors in contrast, genomic heterogeneity is rampant, and a considerably less pro…”
BackgroundKuroda, J., Kimura, S. H., Strasser, A., Andreeff, M., O’Reilly, L. A., Ashihara, E., Kamitsuji, Y., Yokota, A., Kawata, E., Takeuchi, M., et al. (2007) · Cell Death and Differentiation · doi:10.1038/sj.cdd.4402168 · Cited by 66
Bcr-Abl-Mediated Protection from Apoptosis Downstream of Mitochondrial Cytochrome c Release
Deming, P. B., Schafer, Z. T., Tashker, J. S., Potts, M. B., Deshmukh, M., & Kornbluth, S. A. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.23.10289-10299.2004 · Cited by 72
“(C) GST–Apaf-1 (1-543), GST, or GST-Crk protein was incubated with [ -(32)P]ATP in either control GFP (lane C)- or Bcr-Abl (lane B)-expressing cell lysates, and radiolabeling was assessed via autoradiography.”
BackgroundMethodInfluentialLee, T.-S., Ma, W., Zhang, X., Giles, F., Cortes, J., Kantarjian, H., & Albitar, M. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0482 · Cited by 65
“The T315I mutation (18, 19) and some mutations affecting the socalled P-loop of BCR-ABL confer a greater level of resistance to imatinib (16, 17, 20) and even the new tyrosine kinase inhibitors that are currently used and tested in these patients (12, 21).”
Backgroundvon Bubnoff, N. C. C., Veach, D. R., Miller, W. T., Li, W., Sänger, J., Peschel, C., Bornmann, W. G., Clarkson, B., & Duyster, J. (2003) · PubMed · Cited by 75
Imatinib mesylate: Clinical results in Philadelphia chromosome-positive leukemias
Kantarjian, H. M., & Talpaz, M. (2001) · Seminars in Oncology · doi:10.1016/s0093-7754(01)90098-3 · Cited by 70
Mohamed, A. N., Pemberton, P., Zonder, J. A., & Schiffer, C. A. (2003) · PubMed · Cited by 71
Kumar, R., Goel, H., Solanki, R., Rawat, L., Tabasum, S., Tanwar, P., Pal, S., & Sabarwal, A. (2024) · Medicine in Drug Discovery · doi:10.1016/j.medidd.2024.100195 · Cited by 75
Jiang, X., Forrest, D. L., Nicolini, F. E., Turhan, A. G., Guilhot, J., Yip, C. K., Holyoake, T. L., Jørgensen, H. G., Lambie, K., Saw, K. M., et al. (2010) · Blood · doi:10.1182/blood-2009-05-222471 · Cited by 66
Mechanisms of resistance to BCR-ABL and other kinase inhibitors
Lamontanara, A. J., Akçok, E. B. G., Kuzyk, O., & Hantschel, O. D. (2012) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2012.12.009 · Cited by 71
“A mutation in the gatekeeper residue of BCR-ABL, T315I, was the first mutation identified in relapsed CML patients [23].”
BackgroundDasmahapatra, G. P., Yerram, N. K., Dai, Y., Dent, P., & Grant, S. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0835 · Cited by 66
RetractedFoo, J., Drummond, M. W., Clarkson, B. D., Holyoake, T. L., & Michor, F. (2009) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1000503 · Cited by 70
“The evolution of point mutations in the BCR-ABL kinase domain conferring resistance represents a limitation for the usefulness of imatinib therapy [43–47].”
BackgroundTreating cancer's kinase 'addiction'
Baselga, J. M., & Arribas, J. (2004) · Nature Medicine · doi:10.1038/nm0804-786 · Cited by 74
ABT-869, a promising multi-targeted tyrosine kinase inhibitor: from bench to bedside
Zhou, J., Goh, B.-C., Albert, D. H., & Chen, C.-S. (2009) · Journal of Hematology & Oncology · doi:10.1186/1756-8722-2-33 · Cited by 65
“Point mutations in the ATP binding site or gene amplification of BCR-ABL are the main cause of imatinib-resistance in CML patients [47].”
BackgroundCathepsin L inhibition suppresses drug resistance in vitro and in vivo: a putative mechanism
Zheng, X. S., Chu, F., Chou, P. M., Gallati, C., Dier, U., Mirkin, B. L., Mousa, S. A., & Rebbaa, A. (2008) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00082.2008 · Cited by 67
“Important progress has been made in identifying putative mechanisms responsible for this phenomenon (3), such as alterations in drug transport and drug- or target-modifying enzymes (9, 10, 19).”
BackgroundA paradigm for therapy-induced microenvironmental changes in solid tumors leading to drug resistance
Yu, J., Kerbel, R. S., & Coomber, B. L. (2002) · Differentiation · doi:10.1046/j.1432-0436.2002.700913.x · Cited by 71
Tseng, P., Lin, H.-P., Zhu, J., Chen, K., Hade, E. M., Young, D. C., Byrd, J. C., Grever, M. R., Johnson, K. J., Druker, B. J., et al. (2005) · Blood · doi:10.1182/blood-2004-07-2967 · Cited by 69
After chronic myelogenous leukemia: tyrosine kinase inhibitors in other hematologic malignancies
Wadleigh, M., DeAngelo, D. J., Griffin, J. D., & Stone, R. M. (2004) · Blood · doi:10.1182/blood-2003-11-3896 · Cited by 74
Inhibitors of the Abl kinase directed at either the ATP- or myristate-binding site
Fabbro, D., Manley, P. W., Jahnke, W., Liebetanz, J., Szyttenholm, A., Fendrich, G., Strauss, A., Zhang, J., Gray, N. S., Adrián, F., et al. (2010) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2009.12.009 · Cited by 64
Critical molecular pathways in cancer stem cells of chronic myeloid leukemia
Chen, Y., Peng, C., Sullivan, C., Li, D., & Li, S. (2010) · Leukemia · doi:10.1038/leu.2010.143 · Cited by 67
Molecular basis underlying resistance to Mps1/TTK inhibitors
Koch, A., Maia, A. R. R., Janssen, A., & Medema, R. H. (2015) · Oncogene · doi:10.1038/onc.2015.319 · Cited by 68
Larghero, J., Leguay, T., Mourah, S., Madelaine, I., Taksin, A., Raffoux, E., Bastie, J.-N., Degos, L., Berthaud, P., Marolleau, J., et al. (2003) · Biochemical Pharmacology · doi:10.1016/s0006-2952(03)00469-6 · Cited by 71
Molecular mechanisms of resistance of leukemia to imatinib mesylate
Tauchi, T., & Ohyashiki, K. (2003) · Leukemia Research · doi:10.1016/j.leukres.2003.10.007 · Cited by 64
Jabbour, E. J., Cortes, J. E., Kantarjian, H. M., Giralt, S., Andersson, B. S., Giles, F. J., Shpall, E. J., Kebriaei, P., Champlin, R. E., & de Lima, M. (2007) · Cancer · doi:10.1002/cncr.22778 · Cited by 64
Inhibition of BCR/ABL Protein Expression by miR-203 Sensitizes for Imatinib Mesylate
Li, Y., Yuan, Y., Tao, K., Wang, X., Xiao, Q., Huang, Z., Zhong, L., Cao, W., Wen, J., & Feng, W. (2013) · PLoS ONE · doi:10.1371/journal.pone.0061858 · Cited by 63
“However, resistance to imatinib can emerge due to point mutations or BCR/ABL amplification [2].”
BackgroundJapanese Study Group on GIST, Nishida, T., Takahashi, T., Nishitani, A., Doi, T., Shirao, K., Komatsu, Y., Nakajima, K., & Hirota, S. (2009) · International Journal of Clinical Oncology · doi:10.1007/s10147-008-0822-y · Cited by 63
The Role of Nrf2 and Cytoprotection in Regulating Chemotherapy Resistance of Human Leukemia Cells
Rushworth, S. A., & MacEwan, D. J. (2011) · Cancers · doi:10.3390/cancers3021605 · Cited by 69
“particularly in accelerated phase (AP) and blast phase (BP) CML, as well as in acute lymphoblastic leukemia (ALL), and can represent a serious clinical problem [68,69].”
BackgroundValent, P. (2008) · British Journal of Haematology · doi:10.1111/j.1365-2141.2008.07197.x · Cited by 66
“BCR/ABL mutations in stem cell subclones Secondary resistance against imatinib is associated with a frequent occurrence of BCR/ABL1 mutations (about 50% of patients) (Gorre et al, 2001; Barthe et al, 2002; Branford et al, 2002, 2003; von Bubnoff et al, 2002; Hochhaus et al, 2002; Shah et al, 2002).”
BackgroundYang, L., Luo, H., Chen, J., Xing, Q., & He, L. (2009) · Nucleic Acids Research · doi:10.1093/nar/gkp312 · Cited by 67
“Examples include the T790M in the gefitinib binding pocket of EGFR (4); the T164I within the epinephrine binding pocket of b2-adrenergic receptor (27); and the polymorphism within the binding pocket of STI-571 to c-Abl (28).”
BackgroundSelective elimination of leukemia stem cells: Hitting a moving target
Crews, L. A., & Jamieson, C. H. M. (2012) · Cancer Letters · doi:10.1016/j.canlet.2012.08.006 · Cited by 67
“Although a striking reduction in mortality has occurred in patients treated early in chronic phase CML with TKI therapy, ultimately a significant fraction of treated patients develop therapeutic resistance attributed to the persistence of malignant progenitors [21,22].”
BackgroundHassan, B., Akcakanat, A., Sangai, T., Evans, K. W., Adkins, F., Eterovic, A. K., Zhao, H., Chen, K., Chen, H., Do, K.-A., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.2337 · Cited by 61
“A variety of acquired genomic alterations that confer resistance to targeted therapies have been described including acquired Bcr-Abl mutations in response to imatinib treatment [44], ras mutations with cetuximab [45], EGFR mutations [46, 47] MET amplification with EGFR inhibitors[48], and loss of HER2 with trastuzuma…”
Eadie, L. N., Saunders, V. A., Branford, S., White, D. L., & Hughes, T. P. (2018) · Oncotarget · doi:10.18632/oncotarget.24393 · Cited by 63
“ABCB1, ABCG2 and BCR-ABL1 overexpression are previously defined resistance mechanisms to imatinib, nilotinib and dasatinib [24, 26, 30, 33] so, as expected, in the absence of ABCB1/ABCG2 inhibition, LD50IM, LD50NIL and LD50DAS were significantly increased in KU812 10 μM asciminib cells compared with control cells: LD5…”
Inhibition of HMGcoA reductase by atorvastatin prevents and reverses MYC-induced lymphomagenesis
Shachaf, C. M., Perez, O. D., Youssef, S., Fan, A. C., Elchuri, S. V., Goldstein, M. J., Shirer, A. E., Sharpe, O., Chen, J., Mitchell, D. J., et al. (2007) · Blood · doi:10.1182/blood-2006-09-048033 · Cited by 65
Chakraborty, P. K., Mustafi, S. B., Ganguly, S., Chatterjee, M., & Raha, S. (2008) · Cancer Science · doi:10.1111/j.1349-7006.2008.00809.x · Cited by 63
Gardembas, M., Rousselot, P. H., Tulliez, M., Vigier, M., Buzyn, A., Huguet, F., Legros, L., Michallet, M., Berthou, C., Cheron, N., et al. (2003) · Blood · doi:10.1182/blood-2003-04-1010 · Cited by 63
“47% (28-66) 17% (10-42) 23% (10-42) 13% (4-31)”
Xu, X., Wang, D., Sun, X., Zeng, S., Li, L., & Sun, D. (2009) · Thermochimica Acta · doi:10.1016/j.tca.2009.03.017 · Cited by 62
Lin, Y.-L., & Roux, B. (2013) · Journal of the American Chemical Society · doi:10.1021/ja405939x · Cited by 58
Cytogenetic and molecular mechanisms of resistance to imatinib
Hochhaus, A. (2003) · Seminars in Hematology · doi:10.1053/shem.2003.50045 · Cited by 75
Bono, P., Krause, A., von Mehren, M., Heinrich, M. C., Blanke, C. D., Dimitrijević, S., Demetri, G. D., & Joensuu, H. (2004) · Blood · doi:10.1182/blood-2003-10-3443 · Cited by 62
Targeting the molecular pathophysiology of gastrointestinal stromal tumors with imatinib
Demetri, G. D. (2002) · Hematology/Oncology Clinics of North America · doi:10.1016/s0889-8588(02)00052-7 · Cited by 62
Cyclosporine inhibition of P-glycoprotein in chronic myeloid leukemia blast phase
List, A. F., Kopecky, K. J., Willman, C. L., Head, D. R., Slovak, M. L., Douer, D., Dakhil, S. R., & Appelbaum, F. R. (2002) · Blood · doi:10.1182/blood.v100.5.1910.h81702001910_1910_1912 · Cited by 64
le Coutre, P., Kreuzer, K., Na, I., Lupberger, J., Holdhoff, M., Appelt, C., Schwarz, M., Müller, C., Gambacorti-Passerini, C. B., Platzbecker, U., et al. (2002) · Blood Cells Molecules and Diseases · doi:10.1006/bcmd.2002.0493 · Cited by 67
von Bubnoff, N. C. C., Gorantla, S. P., Thoene, S., Peschel, C., & Duyster, J. (2006) · Blood · doi:10.1182/blood-2006-01-0285 · Cited by 62
PDGF Receptor and its Antagonists: Role in Treatment of PAH
Grimminger, F., & SCHERMULY, R. T. (2009) · Advances in experimental medicine and biology · doi:10.1007/978-1-60761-500-2_28 · Cited by 61
Recent Advances in the Molecular Characterization of Circulating Tumor Cells
Lowes, L. E., & Allan, A. L. (2014) · Cancers · doi:10.3390/cancers6010595 · Cited by 62
“, BCR-ABL mutations which confer drug resistance) [121], alternations to copy number (e.”
BackgroundRestoration of miR-424 suppresses BCR–ABL activity and sensitizes CML cells to imatinib treatment
Hershkovitz‐Rokah, O., Modai, S., Pasmanik, M., Toren, A., Shomron, N., Raanani, P., Shpilberg, O., & Granot, G. (2015) · Cancer Letters · doi:10.1016/j.canlet.2015.02.031 · Cited by 61
Tang, C., Schafranek, L., Watkins, D. B., Parker, W. T., Moore, S., Prime, J. A., White, D. L., & Hughes, T. P. (2011) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2011.591013 · Cited by 61
Sundaram, D. N. M., Jiang, X., Brandwein, J. M., Valencia‐Serna, J., Remant, K. C. B., & Uludağ, H. (2019) · Drug Discovery Today · doi:10.1016/j.drudis.2019.05.007 · Cited by 66
Rahmani, M., Nguyen, T. K., Dent, P., & Grant, S. (2007) · Molecular Pharmacology · doi:10.1124/mol.106.033308 · Cited by 62
“For example, mutations in the Bcr/Abl kinase domain (e.g., T315I) induce steric changes in the kinase domain that prevent drug binding and reduce or abrogate activity (Gorre et al., 2001); nevertheless, cells remain dependent on Bcr/Abl for survival.”
BackgroundBöhmer, F., Karagyozov, L. K., Uecker, A., Serve, H. L., Botzki, A., Mahboobi, S., & Dove, S. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m209861200 · Cited by 61
Workman, P., Al‐Lazikani, B., & Clarke, P. A. (2013) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2013.06.004 · Cited by 65
Couturier, M., Thomas, X., Raffoux, E., Huguet, F., Berthon, C., Simand, C., Gallego-Hernanz, M.-P., Hicheri, Y., Hunault, M., Saillard, C., et al. (2020) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2020.1844198 · Cited by 60
Manshouri, T., Quintás‐Cardama, A., Nussenzveig, R. H., Gaikwad, A. S., Estrov, Z. E., Prchal, J. T., Cortes, J. E., Kantarjian, H. M., & Verstovšek, S. (2008) · Cancer Science · doi:10.1111/j.1349-7006.2008.00817.x · Cited by 62
Leder, K., Foo, J., Skaggs, B. J., Gorre, M. E., Sawyers, C. L., & Michor, F. (2011) · PLoS ONE · doi:10.1371/journal.pone.0027682 · Cited by 60
“Clinical resistance to imatinib is primarily mediated by point mutations within the BCR-ABL tyrosine kinase domain [7].”
BackgroundSelf-citationContrasting Hypoxic Effects on Breast Cancer Stem Cell Hierarchy Is Dependent on ER-α Status
Harrison, H., Rogerson, L., Gregson, H. J., Brennan, K. R., Clarke, R. B., & Landberg, G. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-2505 · Cited by 63
“disappointing cancer recurrences after initially promising responses (13, 46).”
BackgroundChronic myeloid leukemia—still a few questions
Goldman, J. M. (2004) · Experimental Hematology · doi:10.1016/j.exphem.2003.10.001 · Cited by 69
Wolff, N. C., Veach, D. R., Tong, W. P., Bornmann, W. G., Clarkson, B. D., & Ilaria, R. L. (2005) · Blood · doi:10.1182/blood-2004-09-3534 · Cited by 65
Detection of Resistance to Imatinib by Metabolic Profiling
Serkova, N. J., & Boros, L. (2005) · American Journal of PharmacoGenomics · doi:10.2165/00129785-200505050-00002 · Cited by 59
Zhang, M., Fu, W., Prabhu, S., Moore, J. C., Ko, J., Kim, J. W., Druker, B. J., Trapp, V., Fruehauf, J. P., Gram, H., et al. (2008) · Molecular and Cellular Biology · doi:10.1128/mcb.00477-08 · Cited by 60
“Because of this encouraging find, we went on to determine the efficacy of this combination against cells bearing imatinibresistant mutants of Bcr-Abl, as well as those overexpressing “wild-type” Bcr-Abl, which together represent the majority of cases of clinical imatinib resistance (8, 31).”
BackgroundPolitou, M., Karadimitris, A., Terpos, E., Kotsianidis, Ι., Apperley, J. F., & Rahemtulla, A. (2005) · Leukemia Research · doi:10.1016/j.leukres.2005.06.014 · Cited by 63
c-Abl Tyrosine Kinase and Inhibition by the Cancer Drug Imatinib (Gleevec/STI-571)
Nagar, B. (2007) · Journal of Nutrition · doi:10.1093/jn/137.6.1518s · Cited by 59
The Therapeutic Implications of Plasticity of the Cancer Stem Cell Phenotype
Leder, K., Holland, E. C., & Michor, F. (2010) · PLoS ONE · doi:10.1371/journal.pone.0014366 · Cited by 59
“Two prominent examples are the point mutations in BCR-ABL and EGFR that confer resistance against the small molecule inhibitors imatinib/dasatinib and erlotinib/gefitinib [25,26].”
BackgroundFang, C., Wang, Y., Vu, N. T., Lin, W., Hsieh, Y., Rubbi, L., Phelps, M. E., Müschen, M., Kim, Y., Chatziioannou, A. F., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-0851 · Cited by 63
“Kinase-related signaling measurements directly from patient samples often involve detecting the consequences of activity, for example the resulting downstream phosphorylation patterns (6-8).”
BackgroundMethodChang, Y. S., Choi, C., & Lee, J. C. (2016) · Tuberculosis & respiratory diseases · doi:10.4046/trd.2016.79.4.248 · Cited by 66
Discovering and validating cancer genetic dependencies: approaches and pitfalls
Lin, A., & Sheltzer, J. M. (2020) · Nature Reviews Genetics · doi:10.1038/s41576-020-0247-7 · Cited by 63
Kimura, S. H., Ito, C., Jyoko, N., Segawa, H., Kuroda, J., Okada, M., Adachi, S., Nakahata, T., Yuasa, T., Filho, V. C., et al. (2004) · International Journal of Cancer · doi:10.1002/ijc.20505 · Cited by 59
Imatinib Resistance: Obstacles and Opportunities
Litzow, M. R. (2006) · Archives of Pathology & Laboratory Medicine · doi:10.5858/2006-130-669-iroao · Cited by 68
BCR‐ABL1 kinase domain mutations: Methodology and clinical evaluation
Alikian, M., Gerrard, G., Subramanian, P. G., Mudge, K., Foskett, P., Khorashad, J. S., Lim, A. C., Marín, D., Milojković, D., Reid, A. G., et al. (2011) · American Journal of Hematology · doi:10.1002/ajh.22272 · Cited by 58
“Compared to CML, the frequency of these mutations is much higher in patients with Ph positive acute lymphoblastic leukemia (ALL) at the time of relapse (80–90%) [13,21,22].”
BackgroundEmerging Therapeutic Strategies for Targeting Chronic Myeloid Leukemia Stem Cells
Hamad, A., Sahli, Z. T., Sabban, M. E., Mouteirik, M., & Nasr, R. (2013) · Stem Cells International · doi:10.1155/2013/724360 · Cited by 58
“BCR-ABL dependent mechanisms of resistance involve duplication or overamplification of the bcr-abl oncogene that might lead to an elevated ABL kinase activity [36, 37].”
BackgroundInhibitors of the anaplastic lymphoma kinase
Mologni, L. (2012) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2012.690031 · Cited by 62
“The same position is exploited by BCR/ABL to survive TKI therapy (the most infamous T315I mutant [71]) and the corresponding EGFR T790M mutation gives complete resistance to EGFR inhibitors [72].”
BackgroundHeaney, N. B., Pellicano, F., Zhang, B., Crawford, L., Chu, S., Kazmi, S. M. A., Allan, E. K., Jørgensen, H. G., Irvine, A. E., Bhatia, R., et al. (2010) · Blood · doi:10.1182/blood-2008-06-164582 · Cited by 61
Cortes, J. E., Nicolini, F. E., Wetzler, M., Lipton, J. H., Akard, L. P., Craig, A., Nanda, N., Benichou, A., Leonoudakis, J., Khoury, H. J., et al. (2013) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2013.03.020 · Cited by 58
Maleddu (2009) · Oncology Reports · doi:10.3892/or_00000361 · Cited by 58
Rodrigues, M. S., Reddy, M. M., & Sattler, M. (2008) · Antioxidants & Redox Signaling · doi:10.1089/ars.2008.2071 · Cited by 57
“To date, (cid:6) 50 different point mutations encoding distinct single amino-acid substitutions in the BCR–ABL kinase domain have been identified in 50–90% of relapsed CML patients (38, 39, 126, 157, 332).”
Resistance to Imatinib: Mechanisms and Management
Deininger, M. W. (2005) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2005.0045 · Cited by 58
BCR-ABL1 mediates up-regulation of Fyn in chronic myelogenous leukemia
Ban, K., Gao, Y. H., Amin, H. M., Howard, A., Miller, C. P., Lin, Q. D., Leng, X., Munsell, M., Bar‐Eli, M., Arlinghaus, R. B., et al. (2008) · Blood · doi:10.1182/blood-2007-05-091769 · Cited by 58
Gruber, F., Mustjoki, S. M., & Porkka, K. (2009) · British Journal of Haematology · doi:10.1111/j.1365-2141.2009.07666.x · Cited by 64
Natural selection in neoplastic progression of Barrett's esophagus
Maley, C. C., & Reid, B. J. (2005) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2005.06.004 · Cited by 58
“[7] Gorre ME, Mohammed M, Ellwood K, Hsu N, Paquette R, Rao PN, et al.”
BackgroundSpiekermann, K., Faber, F., Voswinckel, R., & Hiddemann, W. (2002) · Experimental Hematology · doi:10.1016/s0301-472x(02)00837-8 · Cited by 58
“As recently shown, STI 571–resistant mutants of BCR-ABL evolved in CML cells from patients who develop a clinical resistance to STI 571 during therapy with the inhibitor [34].”
BackgroundInhibition of RET tyrosine kinase by SU5416
Mologni, L., Sala, E., Cazzaniga, S., Rostagno, R., Kuoni, T., Puttini, M., Bain, J., Cleris, L., Redaelli, S., Riva, B., et al. (2006) · Journal of Molecular Endocrinology · doi:10.1677/jme.1.01999 · Cited by 57
Kang, H., Hwang, J., Kim, S.-H., Goh, H., Kim, M., & Kim, D.-W. (2006) · PubMed · Cited by 58
Mechanisms of Disease: preclinical reports of antineoplastic synergistic action of bisphosphonates
Santini, D., Caraglia, M., Vincenzi, B., Holen, I., Scarpa, S., Budillon, A., & Tonini, G. (2006) · Nature Clinical Practice Oncology · doi:10.1038/ncponc0520 · Cited by 63
STI571 as a Targeted Therapy for CML
O'Dwyer, M. E., Mauro, M. J., & Druker, B. J. (2003) · Cancer Investigation · doi:10.1081/cnv-120018235 · Cited by 63
“Other mechanisms of resistance that might be operative with a gene-targeted therapeutic agent include target gene amplification,([41,42]) bcr-abl mutation,([43]) or overexpression of multidrug resistance protein.”
BackgroundCommentary: Novel Therapies for Cancer: Why Dirty Might Be Better
Fojo, T. (2008) · The Oncologist · doi:10.1634/theoncologist.2007-0090 · Cited by 59
The multi-molecular mechanisms of tumor-targeted drug resistance in precision medicine
Li, X., Li, M., Huang, M., Lin, Q., Fang, Q., Liu, J., Chen, X., Liu, L., Zhan, X., Shan, H., et al. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.113064 · Cited by 63
Cortes, J. E., Sasaki, K., Kim, D.-W., Hughes, T. P., Etienne, G., Mauro, M. J., Hochhaus, A., Lang, F., Heinrich, M. C., Breccia, M., et al. (2024) · Leukemia · doi:10.1038/s41375-024-02278-8 · Cited by 56
Mauro, M. J., Hughes, T. P., Kim, D.-W., Rea, D., Cortes, J. E., Hochhaus, A., Sasaki, K., Breccia, M., Talpaz, M., Ottmann, O., et al. (2023) · Leukemia · doi:10.1038/s41375-023-01860-w · Cited by 53
Metadata
- Authors
- Gorre, M. E., Mohammed, M., Ellwood, K., Hsu, N., Paquette, R., Rao, P. N., & Sawyers, C. L.
- Affiliations
- University of California, Los Angeles (US)
- Department of Pathology, and
- Department of Medicine,
- Corresponding author
- Sawyers, Charles L.
- Venue
- Science
- Published
- 2001-08-03
- Volume
- 293
- Issue
- 5531
- Pages
- 876-880
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W1999614615
- Cited by
- 3,104
- References
- 26
- Citations by year
- 2026: 32 · 2025: 33 · 2024: 45 · 2023: 64 · 2022: 44 · 2021: 60 · 2020: 71 · 2019: 76 · 2018: 68 · 2017: 84 · 2016: 96 · 2015: 106 · 2014: 141 · 2013: 169 · 2012: 162
- FWCI
- 85.12
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute of General Medical Sciences (GM-07185, T32GM007185)
- Topics
- Health Sciences › Medicine › Hematology › Chronic Myeloid Leukemia Treatments
- Health Sciences › Medicine › Hematology › Chronic Lymphocytic Leukemia Research
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Keywords
- imatinib, BCR-ABL, chronic myeloid leukemia, drug resistance, Abl tyrosine kinase, BCR-ABL mutations, relapse
- MeSH terms
- Imatinib Mesylate, Amino Acid Sequence, Antineoplastic Agents, Base Sequence, Benzamides, Blast Crisis, Cell Line, Gene Amplification, Humans, Hydrogen Bonding, Molecular Sequence Data, Philadelphia Chromosome, Phosphorylation, Piperazines, Proto-Oncogene Proteins, Pyrimidines, Recurrence, Signal Transduction, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Fusion Proteins, bcr-abl, Genes, abl, Proto-Oncogene Proteins c-abl, Point Mutation, Protein Structure, Tertiary, Drug Resistance, Neoplasm, Amino Acid Substitution, Proto-Oncogene Proteins c-crk
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.